Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors

Areas covered: The aim of the current review is to present an update on the role of MEK in progressive melanomas and summarize latest results of clinical studies with innovative MEK inhibitors and/or combined approaches with other kinase inhibitors such as BRAF inhibitors in the treatment of MM

Elnaz Faghfuri

2018

Scholarcy highlights

  • Malignant melanoma is an aggressive disease with a rapidly rising incidence due to neoplasm of melanocytes
  • Areas covered: The aim of the current review is to present an update on the role of MEK in progressive melanomas and summarize latest results of clinical studies with innovative MEK inhibitors and/or combined approaches with other kinase inhibitors such as BRAF inhibitors in the treatment of MM
  • The simultaneous prohibition of both MEK and BRAF is associated with more durable response rate than BRAF monotherapy and can overcome acquired resistance
  • Clinical studies using MEKi as monotherapy has been unsatisfactory in patients previously treated with a BRAFi
  • You are consenting to our use of cookies

Need more features? Save interactive summary cards to your Scholarcy Library.